ImmunoGuide® Enzyme immunoassay (ELISA) for the semi-quantitative determination of free antibodies to Vedolizumab (Entyvio®) in serum and plasma.<br><br>
The drug Vedolizumab (trade name Entyvio®) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7, is indicated for the treatment of moderately to severely active ulcerative colitis [UC] or Crohn’s disease [CD]. During treatment the presence of persistent anti-Vedolizumab antibody was observed to substantially reduce serum concentrations of Vedolizumab, either to undetectable or negligible levels.<br><br>
The ImmunoGuide Antibody to Vedolizumab ELISA kit has been designed for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 1 hour (RT) + 15 min. (RT) = 2 hour, 15 min. total incubation time
- Catalog number:
- TM09032
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- Positive control
- design:
- Enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Entyvio®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- Standard range:
- 0 / 5 - 150 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 5 ng/mL
- Species:
- Human
- Additional info:
